[1] |
Kwiatkowski J, Kuliszkiewicz-Janus M, Potoczek S, et al. What factors determine the pregnancy outcome in patients with essential thrombocythemia?[J]. J Matern Fetal Neonatal Med, 2022, 35(24):4734-4738. doi: 10.1080/14767058.2020.1863362.
|
[2] |
Edahiro Y. Treatment options and pregnancy management for patients with PV and ET[J]. Int J Hematol, 2022, 115(5):659-671. doi: 10.1007/s12185-022-03336-6.
pmid: 35394259
|
[3] |
Tefferi A, Gangat N, Loscocco GG, et al. Essential Thrombocythemia: A Review[J]. JAMA, 2025, 333(8):701-714. doi: 10.1001/jama.2024.25349.
|
[4] |
Regan L, Rai R, Saravelos S, et al. Recurrent MiscarriageGreen-top Guideline No. 17[J]. BJOG, 2023, 130(12):e9-e39. doi: 10.1111/1471-0528.17515.
|
[5] |
Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2024, 99(4):697-718. doi: 10.1002/ajh.27216.
pmid: 38269572
|
[6] |
Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia[J]. Am J Hematol, 2014, 89(3):306-309. doi: 10.1002/ajh.23635.
pmid: 24265194
|
[7] |
Hristova M. Overcoming Recurrent Miscarriages in a 35-Year-Old Female With Thrombophilia[J]. Cureus, 2024, 16(6):e62870.doi: 10.7759/cureus.62870.
|
[8] |
Rahman K, Biswas S, Sharma A, et al. Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm-A single-center study from North India[J]. Indian J Pathol Microbiol, 2024, 67(4):739-746. doi: 10.4103/ijpm.ijpm_743_23.
|
[9] |
Zhang Y, Zhao Y, Liu Y, et al. New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms[J]. Cancer, 2024, 130(24):4229-4240. doi: 10.1002/cncr.35559.
pmid: 39277798
|
[10] |
Maze D, Arusi I, Gupta V, et al. Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms[J]. EJHaem, 2023, 4(1):241-245. doi: 10.1002/jha2.622.
pmid: 36819152
|
[11] |
Gangat N, Singh A, Ilyas R, et al. Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia-A Mayo Clinic study of 200 pregnancies[J]. Am J Hematol, 2024, 99(10):1862-1869. doi: 10.1002/ajh.27416.
pmid: 38867546
|
[12] |
Tefferi A, Barbui T. Aspirin use in essential thrombocythemia: Once-daily or twice-daily or not at all?[J]. Am J Hematol, 2024, 99(8):1450-1453. doi: 10.1002/ajh.27369.
pmid: 38752361
|
[13] |
Xiong F, Wang Q, Wu GH, et al. Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow[J]. Biomark Res, 2022, 10(1):69. doi: 10.1186/s40364-022-00415-y.
pmid: 36104718
|
[14] |
Kiladjian JJ. Pegylated interferon: the who, why, and how[J]. Hematology Am Soc Hematol Educ Program, 2024, 2024(1):535-540. doi: 10.1182/hematology.2024000577.
|
[15] |
Vaupel P, Multhoff G. Blood Flow and Respiratory Gas Exchange in the Human Placenta at Term: A Data Update[J]. Adv Exp Med Biol, 2022,1395:379-384. doi: 10.1007/978-3-031-14190-4_62.
|